Кенія - англійська - Pharmacy and Poisons Board

medley pharmaceuticals limited medley pharmaceuticals ltd. medley house d2 - cefuroxime axetil tablets usp 500 mg - tablet - cefuroxime axetil usp 500 mg per tablet - beta-lactamantibacterials: second-generation

Нова Зеландія - англійська - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - misoprostol 200ug (misoprostol:hpmc dispersion 1:100 = 20.2mg/tablet) - tablet - 200 mcg - active: misoprostol 200ug (misoprostol:hpmc dispersion 1:100 = 20.2mg/tablet) excipient: hydrogenated castor oil microcrystalline cellulose sodium starch glycolate - cytotec is indicated for coadministration with non-steroidal anti-inflammatory drugs (nsaids) for the prevention of ulcers and erosions induced by nsaids in adults. cytotec is indicated for the treatment of duodenal and gastric ulcers in adults. cytotec is also effective in healing a significant number of duodenal ulcers refractory to h2-blocker therapy. cytotec is indicated for the treatment of erosive gastroduodenitis associated with peptic ulcer disease in adults. cytotec is indicated in prevention of stress-induced upper gi mucosal bleeding and lesions in post-surgical adult icu patients.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - apixaban, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose; sodium lauryl sulfate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow - eliquis is indicated for the prevention of venous thromboembolic events (vte) in adult patients who have undergone elective total hip or total knee replacement surgery.,eliquis is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,eliquis is indicated for the treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) in adult patients.,eliquis is indicated for the prevention of recurrent dvt and pe in adult patients.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - apixaban, quantity: 5 mg - tablet, film coated - excipient ingredients: sodium lauryl sulfate; microcrystalline cellulose; lactose; purified water; magnesium stearate; croscarmellose sodium; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - eliquis is indicated for the prevention of venous thromboembolic events (vte) in adult patients who have undergone elective total hip or total knee replacement surgery.,eliquis is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,eliquis is indicated for the treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe) in adult patients.,eliquis is indicated for the prevention of recurrent dvt and pe in adult patients.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 0.03 mg; gestodene, quantity: 0.075 mg - tablet, sugar coated - excipient ingredients: brilliant scarlet 4r; magnesium stearate; macrogol 6000; calcium carbonate; lactose monohydrate; erythrosine; purified talc; maize starch; sucrose; glycol montanate; povidone - for the prevention of pregnancy.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - tadalafil, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; hypromellose; sorbitan stearate; magnesium stearate; titanium dioxide; purified talc; triacetin; iron oxide yellow - tadalafil 20 mg tablets is indicated in adults for the treatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity. efficacy has been shown in idiopathic pah (ipah) and in pah related to collagen vascular disease.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lansoprazole, quantity: 15 mg - tablet, orally disintegrating - 15 mg - excipient ingredients: iron oxide yellow; polysorbate 80; purified talc; microcrystalline cellulose; titanium dioxide; lactose monohydrate; aspartame; hyprolose; macrogol 8000; iron oxide red; magnesium carbonate hydrate; magnesium stearate; crospovidone; mannitol; glyceryl monostearate; hypromellose; triethyl citrate; citric acid; polyacrylate dispersion (30 per cent); purified water; methacrylic acid copolymer; sodium lauryl sulfate; flavour - adults 1. healing and long-term management of reflux oesophagitis. 2. healing and long-term management for patients with duodenal ulcer. 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. paediatric patients 6 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. 2. healing of erosive oesophagitis.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 36 microgram; norethisterone, quantity: 1 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; povidone; magnesium stearate - indications as at 31 august 1998 : contraception

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - norethisterone, quantity: 500 microgram; ethinylestradiol, quantity: 36 microgram - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose; sunset yellow fcf; lactose monohydrate - 31 august 1998 : contraception

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - lansoprazole, quantity: 30 mg - tablet, orally disintegrating - excipient ingredients: iron oxide yellow; macrogol 8000; hypromellose; hyprolose; magnesium carbonate hydrate; citric acid; magnesium stearate; crospovidone; iron oxide red; triethyl citrate; microcrystalline cellulose; polysorbate 80; mannitol; aspartame; glyceryl monostearate; titanium dioxide; purified talc; lactose monohydrate; flavour; purified water; methacrylic acid copolymer; sodium lauryl sulfate; polyacrylate dispersion (30 per cent) - adults 1. healing and long-term management of reflux oesophagitis. 2. healing and long-term management for patients with duodenal ulcer. 3. healing of benign gastric ulcer. patients whose gastric or duodenal ulcer is not associated with ingestion of non-steroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory drugs whether on first presentation or on recurrence. 4. lansoprazole is also effective in patients with benign peptic lesions that do not respond to h2-receptor antagonists. 5. eradication of h. pylori from the upper gastrointestinal tract in patients with peptic ulcer or chronic gastritis when used in combination with appropriate antibiotics (see clinical trials). 6. relief of reflux-like and/or ulcer-like symptoms associated with acid-related dyspepsia. paediatric patients 6 to 17 years of age. 1. treatment of gastro-oesophageal reflux disease, including all grades of oesophagitis. 2. healing of erosive oesophagitis.